Roivant Sciences

Roivant Sciences

Roivant Sciences

Focused on the late-stage clinical development and commercialization of nonstrategic, deprioritized or under-resourced drug candidates.
Type
B2b
Founded
2014
Raised
$1.3B
Follow us
Featured on
Alexa global traffic share
Twitter followers
Latest funding
$200,000,000
Private equity - 2018
RTW Investments NovaQuest Capital Management
$1,100,000,000
Private equity - 2017
SoftBank
Team Size
200+
Employees
Pulse 2.0

Montes Archimedes Acquisition (MAAC) Taking Roivant Sciences Public In $7.3 Billion Deal

MedCity News

Roivant Sciences launches new Alyvant subsidiary

$200,000,000 Private equity
PE HUB , MedCity News , CrunchBase

Roivant Sciences pulls in $200 mln

TechCrunch

Roivant receives bad news — and so does Softbank

Health
$1,100,000,000 Private equity
BI Tech , Techvibes , PE HUB

A 32-year-old biotech CEO just raised $1.1 billion from SoftBank to give old drugs new life